《新股消息》藥師幫(09885.HK)公開發售定價20元 一手中籤率30%
內地醫藥產業服務平台藥師幫(09885.HK)公布招股結果,每股發售價定為20元,而招股價範圍為19至23元,香港公開發售部分錄得超額認購約4.6倍。每手200股計,一手中籤率30.01%,認購6手即1,200股才穩獲一手。該股將於明日(28日)掛牌。獨家保薦人為中金公司。
公司是次上市引入中關村發展集團旗下ZGC International為基石投資者,認購501.44萬股,佔緊隨全球發售完成後公司已發行股本總額的約0.79%。
此外,公司上市料淨集資約2.15億元,當中約45%將用於進一步發展公司的醫藥流通業務;約25%將用於進一步發展其他業務;約22%將用於研發;及約8%將用作營運資金及一般企業用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.